Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

     Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076

Patent Covers Composition of Matter and Uses for Various Cancers

PR Newswire

ROCKVILLE, Md., May 6, 2013

ROCKVILLE, Md., May 6, 2013 /PRNewswire/ --EntreMed, Inc. (Nasdaq: ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, today announced the issuance by the Chinese
State Intellectual Property Office of Patent Certificate No. ZL
200680044656.7.The granted claims are directed to ENMD-2076, covering
composition of matter and uses to treat various cancers. The patent is part
of EntreMed's broad intellectual property portfolio for ENMD-2076.

(Logo: )

"We are very pleased with the issuance of this patent in China for ENMD-2076,"
said Ken K. Ren, Ph.D., the Company's Chief Executive Officer. "This patent
provides intellectual property protection for ENMD-2076 in a market that is
experiencing tremendous growth and of which we intend to capitalize on. The
issuance of this patent broadens our existing international patent estate for
ENMD-2076 and also confirms the Chinese State Intellectual Property Office's
recognition that ENMD-2076 represents new and inventive chemical structures."

ENMD-2076 has completed and shown activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, multiple myeloma, and is completing a Phase 2 trial
for ovarian cancer. A Phase 2 triple-negative breast cancer trial at the
University of Colorado and Indiana University and aPhase 2 trial in
advanced/soft tissue sarcoma at Princess Margaret Hospital arecurrently
enrolling. As part of its global development strategy utilizing China
resources, EntreMed has submitted a new drug clinical trial application with
the Chinese Food and Drug Administration (CFDA) for ENMD-2076 to conduct
global clinical trials in triple-negative breast cancer patients.

About EntreMed

EntreMed is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market. Its lead compound, ENMD-2076, a
selective angiogenic kinase inhibitor, has completed several Phase 1 studies
in solid tumors, multiple myeloma, and leukemia, and is currently completing a
multi-center Phase 2 study in ovarian cancer. EntreMed is currently
conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer and a
Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma. The
Company is headquartered in Rockville, Maryland and has local operations in
Beijing, China. Additional information about EntreMed is available on the
Company's web site at and in various filings with the
Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action.
ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine
kinase targets in addition to the Aurora A kinase. Aurora kinases are key
regulators of mitosis (cell division), and are often over-expressed in human
cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have
been shown to play important roles in the pathology of several cancers.
ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, and multiple myeloma, and is currently completing a
Phase 2 trial for ovarian cancer. EntreMed is currently conducting a
dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer
and a Phase 2 study in advanced/metastatic soft tissue sarcoma. ENMD-2076 has
received orphan drug designation from the FDA for the treatment of ovarian
cancer, multiple myeloma and acute myeloid leukemia.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate or future candidates; risks
relating to the need for additional capital and the uncertainty of securing
additional funding on favorable terms; declines in actual sales of Thalomid^®
resulting in reduced or no royalty payments; risks associated with our product
candidates; any early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results; uncertainties
relating to preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical development
of any of our products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks). Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition. We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at

Investor Relations
EntreMed, Inc.

SOURCE EntreMed, Inc.

Press spacebar to pause and continue. Press esc to stop.